Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment (J Neurooncol, (2015), 121,(251-259), DOI 10.1007/s11060-014-1637-5);PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment

Journal of Neuro-Oncology

Volumn 121, Issue 2, 2015, Pages 251-259

  Mathios, Dimitrios ^b   Ruzevick, Jacob ^b   Jackson, Christopher M ^b   Xu, Haiying ^b   Shah, Sagar ^b   Taube, Janis M ^b   Burger, Peter C ^b   McCarthy, Edward F ^b   Quinones Hinojosa, Alfredo ^b   Pardoll, Drew M ^b   Lim, Michael ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B7 H1; Chordomas; PD 1; PD L1; PD L2

Indexed keywords

MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN;

ARTICLE; CHORDOMA; CLINICAL ARTICLE; CLIVUS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMBAR VERTEBRA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SACRUM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; MACROPHAGE; METABOLISM; MICROPHOTOGRAPHY; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTIGENS, CD274; CELL LINE, TUMOR; CHORDOMA; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; PHOTOMICROGRAPHY; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84925467372     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2130-0     Document Type: Erratum

References (32)

1. Salisbury JR (1993) The pathology of the human notochord. J Pathol 171:253–255. doi:10.1002/path.1711710404
2. Feigl GC et al (2005) Evaluation of a new concept for the management of skull base chordomas and chondrosarcomas. J Neurosurg 102(Suppl):165–170
3. Abdulrauf SI (2013) Decision-making process for the treatment of Intracranial chordomas. World Neurosurg. doi:10.1016/j.wneu.2013.07.117
4. Siu IM et al (2013) Erlotinib inhibits growth of a patient-derived chordoma xenograft. PLoS One 8:e78895. doi:10.1371/journal.pone.0078895
5. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001) Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 12:1–11
6. Pillay N et al (2012) A common single-nucleotide variant in T is strongly associated with chordoma. Nat Genet 44:1185–1187. doi:10.1038/ng.2419
7. Bruderlein S et al (2010) Molecular characterization of putative chordoma cell lines. Sarcoma 2010:630129. doi:10.1155/2010/630129
8. Tamborini E et al (2010) Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro-oncology 12:776–789. doi:10.1093/neuonc/noq003
9. Siu IM et al (2012) Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg 116:801–809. doi:10.3171/2011.12.JNS111123
10. Trucco MM et al (2013) A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-kappaB signaling in chordoma biology. PLoS One 8:e79950. doi:10.1371/journal.pone.0079950
11. Nirschl CJ, Drake CG (2013) Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 19:4917–4924. doi:10.1158/1078-0432.CCR-12-1972
12. Akbay EA et al (2013) Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. doi:10.1158/2159-8290.CD-13-0310
13. Bigelow E et al (2013) Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp. doi:10.3791/4059
14. Bloch O et al (2013) Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 19:3165–3175. doi:10.1158/1078-0432.CCR-12-3314
15. Fang L et al (2013) The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro-oncology 15:1479–1490. doi:10.1093/neuonc/not110
16. Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M (2013) Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol 107:517–522. doi:10.1002/jso.23281
17. Yang W, Song Y, Lu YL, Sun JZ, Wang HW (2013) Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 139:513–522. doi:10.1111/imm.12101
18. Hsu W et al (2011) Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J Neurosurg 115:760–769. doi:10.3171/2011.5.JNS11185
19. Lipson EJ et al (2013) Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19:462–468. doi:10.1158/1078-0432.CCR-12-2625
20. Taube JM et al (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra137. doi:10.1126/scitranslmed.3003689
21. de Castro CV et al (2013) Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome. Hum Pathol 44:1747–1755. doi:10.1016/j.humpath.2012.11.024
22. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M (2011) Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol 2011:732413. doi:10.1155/2011/732413
23. Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18:6580–6587. doi:10.1158/1078-0432.CCR-12-1362
24. Shultz LD et al (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174(10):6477–6489. doi:10.4049/jimmunol.174.10.6477
25. Andorsky DJ et al (2011) Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clini Cancer Res 17:4232–4244. doi:10.1158/1078-0432.CCR-10-2660
26. Loke P, Allison JP (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 100:5336–5341. doi:10.1073/pnas.0931259100
27. Yao Y et al (2009) B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol 11(6):757–766
28. Poli A et al (2013) Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget 4:1527–1546
29. Dannenmann SR et al (2013) Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2:e23562. doi:10.4161/onci.23562
30. Campbell MJ et al (2013) The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One 8:e79114. doi:10.1371/journal.pone.0079114
31. Rodrigues JC et al (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-oncology 12:351–365. doi:10.1093/neuonc/nop023
32. Dziurzynski K et al (2011) Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clinical Cancer Res 17:4642–4649. doi:10.1158/1078-0432.CCR-11-0414